Traws Pharma, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Traws Pharma, Inc. (TRAW) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $8.18 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-30.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2015-03-30
- Traws Pharma, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2012-12-31 was $0.00.
- Traws Pharma, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2012 was $8.18M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $8.18M 10-K · filed 2015-03-30 | |
| 2012-09-30 | $8.18M 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |